This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. These symptoms reduce patients' capacity for daily social and physical activity.
A team at Allina Health’s Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. I felt weak and tired all the time and knew I didn’t want to spend my life sitting in the living room chair.
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heartfailurehospitalizations and improves quality of life vs optimal medical therapy alone.
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices.
We hope to identify high-risk patients for early intervention to reduce the incidence of HF and improve their quality of life. The patients were divided into an experimental group (HF patients) and a normal control group.
Although heartfailure prognosis is grim, the ALT-FLOW trials two year results suggest that diverting blood from the left atrium to the coronary sinus using a shunt could have lasting benefits for patients with HFmrEF/HFpEF. By year two, this improved to 85.5% of patients experiencing class I or II symptoms.
milla1cf Tue, 05/28/2024 - 07:00 May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heartfailure, according to research presented at HeartFailure 2024 , a scientific congress of the European Society of Cardiology (ESC).
ABSTRACT Aims Heartfailure outcomes remain poor despite advances in therapy. The European Society of Cardiology HeartFailure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heartfailure by targeting the left ventricle.
Heartfailure is a major health concern, especially for aging populationsit significantly increases mortality rates, and severely impacts quality of life of those affected. Exercise therapy has been shown to be particularly effective for patients with heartfailure.
Iron deficiency (ID) is a common comorbidity among patients with heartfailure (HF), and it is associated with reduced exercise tolerance and quality of life and serves as a marker of increased risk of hospitalizations and mortality.
12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heartfailure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.
Circulation: HeartFailure, Ahead of Print. Compared with cold and wet patients, cold and dry patients also had better baseline functional capacity and quality of life and experienced milder improvements after LVAD: EuroQol (+0.11 versus +0.17;P=0.001),
Background Electrical muscle stimulation (EMS) is being evaluated as a possible alternative to exercise training to improve functional capacity in severely deconditioned patients with heartfailure (HF). However, there is insufficient data on delayed effects of EMS starting early after decompensation.
Background Atrial fibrillation (AF) is common in individuals with heartfailure (HF). Individuals with HF and AF may have a reduced functional capacity and quality of life (QoL) which leads to hospital admission and burden on clinical services. Results 149 individuals were propensity matched from each group.
In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. The late breaking research was presented by principal investigator Martin S. Cytokinetics Inc. provided the funding for this study.
ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heartfailure (HF).MethodsFrom and improved patients’ quality of life scores.
Background Heartfailure (HF) remains a major public health problem with a high mortality and morbidity worldwide. The primary endpoint assessed the key safety outcomes, the secondary endpoints were: the quality of life measured, the N-terminal pro-B-type natriuretic peptide (NT-proBNP) changes and 6 min walk test (6MWT).
Circulation: HeartFailure, Ahead of Print. The strongest independent predictors of a greater improvement in QoL were younger age (P<0.001), no HF hospitalization in the previous year (P<0.001), lower NYHA class before hospital admission (P<0.001) and high-intensity care treatment (mean difference, 4.2 [95%
“Patients suffering with tricuspid regurgitation endure life-impairing symptoms and, until today, had no approved transcatheter treatment options,” said Susheel Kodali, MD , director, Structural Heart and Valve Center at Columbia University Irving Medical Center/New York-Presbyterian Hospital and TRISCEND II Study Principal Investigator.
A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. and Allina Health. and Allina Health.
Decline in exercise ability is a hallmark of progression to overt heartfailure. These results also speak to the importance of continuing to focus on earlier recognition of heartfailure risk in patients with diabetes and on initiating treatment before the condition has progressed to overt heartfailure.”
This 2023 Cochrane review of 60 randomized trials in 8728 heartfailure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life.
Background:Patients with heartfailure may suffer from symptom distress, affecting their overall quality of life and psychological well-being including depression. The control group followed routine hospital care. Circulation, Volume 150, Issue Suppl_1 , Page A4138578-A4138578, November 12, 2024.
Aims Iron deficiency (ID) is common in patients with heartfailure (HF) and is associated with poor outcomes, regardless of anaemia status. Iron supplementation has been demonstrated to improve exercise capacity and quality of life in patients with HF with an ejection fraction <50% and ID.
Introduction:Guidelines have recognized the critical role of self-care in heartfailure (HF), but people with HF do not adequately practice self-care. Participants were recruited from a university-affiliated hospital and randomized at a 1:1 ratio into the intervention or the control groups.
BACKGROUND:The extent of cardiac damage has been shown to be associated with increased mortality, repeat hospitalization, and decreased quality of life after aortic valve replacement (AVR). Circulation: Cardiovascular Interventions, Ahead of Print.
Introduction:Given the well-documented benefits of yoga on the cardiovascular system and improvement of exercise tolerance and quality of life, the American Heart Association recently recommended yoga as a safe and well-tolerated adjunctive therapy for patients with heartfailure (HF).
1 CSP offers an elegant treatment solution to the challenging problem of heartfailure (HF) caused by electrical dyssynchrony due to left bundle branch block (LBBB). Cardiac resynchronization therapy improves survival and quality of life and reduces HF hospitalizations in HF patients with LBBB.1
He led the structural heart program and cardiac catheterization laboratory at the University of Cincinnati and spent several years with The Christ Hospital in Ohio. There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies.
Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. Clinicians working with older patients have witnessed firsthand how polypharmacy can complicate both their care and diminish quality of life.
Previous studies about heart valve disease have focused on procedural or device outcomes, and less on patient-centered and disease-related outcomes that are relevant to patients physical and mental well-being and quality of life.
Abstract Continuous flow left ventricular assist devices (CF-LVADs) have been shown to reduce mortality and morbidity in patients with advanced heartfailure with reduced ejection fraction.
BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
As a result, healthcare faces rising expenses from frequent emergency room visits, lengthy hospital stays, costly procedures like stent placements and bypass surgeries, as well as the long-term management of chronic conditions like heartfailure (HF). These costs represent a massive portion of total health expenditures.
CMS has reviewed the CardiAMP HeartFailure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP HeartFailure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
Abstract Right-sided heartfailure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heartfailurehospitalizations and death. This article is protected by copyright. All rights reserved.
a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of HeartFailure. The manuscript is available online at the European Journal of HeartFailure website.
ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heartfailure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes. The primary outcome was a composite of cardiovascular death or worsening heartfailure. 0.93]; COPD: HR 0.82 [95% CI 0.62–1.10];
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content